Highlights from ASCO GU 2017

Viewing 1-20 of 100 articles

ASCO 2017: Identifying and Targeting Genetic Drivers in Rare Genitourinary Cancer Types

ASCO GU: Evaluation of Sexual Function on a Randomized Trial of a Prostate Rectal Spacer

ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Medical Oncology - Session Highlights

ASCO GU 2017: Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicenter prospective GETUG trial. - Session Highlights

ASCO GU 2017: 111- A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). - Session Highlights

ASCO GU 2017: Dacomitinib (Daco) induction therapy for locally advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase II study. - Session Highlights

ASCO GU 2017: Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. - Session Highlights

ASCO GU 2017: BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer - Session Highlights

ASCO GU 2017: Resection margins after radical cystectomy at academic versus community cancer centers. - Session Highlights

ASCO GU 2017: Characterizing the costs of complications after cystectomy: Can we target the primary drivers? - Session Highlights

ASCO GU 2017: Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. - Session Highlights

ASCO GU 2017: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer - Session Highlights

ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights

ASCO GU 2017: Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. - Session Highlights

ASCO GU 2017: Optimal Selection of Front-Line Therapies for Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights

ASCO GU 2017: Evolving Treatment Using Tyrosine Kinase Inhibitors and Immunotherapy in Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights

ASCO GU 2017: Imaging as Biomarker of Response in Advanced Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC) - Session Highlights

1
2
3
4
5